SRI-37330

Research use only, not for human use.

SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production, and reverses hepatic steatosis.

SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production, and reverses hepatic steatosis.

SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells.SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells.SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter.SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells.SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes.RT-PCR Cell Line:INS-1 cells Concentration:1 μM Incubation Time:24 h Result:Inhibited endogenous TXNIP mRNA expression with an IC50 of 0.64 μM.

SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output.SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice.SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice. Animal Model:C57BL/6J mice Dosage:100 mg/kg Administration:Oral administration (p.o.), in drinking water, 3 weeks.Result:Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.

——

Others

Other Targets

CK2

——

——

2322245-42-9

388.41

C16H19F3N4O2S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (257.46 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years